Prevalence and Factors Associated with Hydatidiform Mole among Patients Undergoing Uterine Evacuation at Mbarara Regional Referral Hospital by Mulisya, Olivier et al.
Research Article
Prevalence and Factors Associated with Hydatidiform
Mole among Patients Undergoing Uterine Evacuation at
Mbarara Regional Referral Hospital
Olivier Mulisya ,1 Drucilla J. Roberts,2 Elizabeth S. Sengupta,3 Elly Agaba,4
Damaris Laffita,4 Tusabe Tobias,3 Derrick Paul Mpiima ,4 Lugobe Henry ,4
Ssemujju Augustine,4 Masinda Abraham,4 Twizerimana Hillary,4 and Julius Mugisha5
1University of Goma, Goma, Democratic Republic of the Congo
2Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA
3Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
4Mbarara University of Science and Technology, Mbarara, Uganda
5Makerere University, Kampala, Uganda
Correspondence should be addressed to Olivier Mulisya; omulisya1@gmail.com
Received 8 June 2017; Revised 19 August 2017; Accepted 8 February 2018; Published 1 April 2018
Academic Editor: Robert Coleman
Copyright © 2018 Olivier Mulisya et al. 'is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Objective. We sought to determine the prevalence of and factors associated with hydatidiform molar gestations amongst patients
undergoing uterine evacuation at Mbarara Regional Referral Hospital (MRRH), Mbarara, Uganda. Methods. 'is was a cross-
sectional study carried out from November 2016 to February 2017. All patients admitted for uterine evacuation for nonviable
pregnancy were included. 'e study registered 181 patients. Data were collected on sociodemographics, medical conditions,
obstetrics, and gynecological factors. 'e evacuated tissue received a full gross and histopathologic examination. Cases of
pathologically suspected complete hydatidiform mole were confirmed by p57 immunohistochemistry. Data were analyzed using
STATA 13. Results. 'e prevalence of hydatidiformmole was 6.1% (11/181). All detected moles were complete hydatidiformmoles,
and there were no diagnosed partial hydatidiform moles. Clinical diagnosis of molar pregnancy was suspected in 13 patients, but
only 69.2% (9/13) were confirmed as molar pregnancies histologically. Two cases were clinically unsuspected. Factors that
had a significant relationship with complete hydatidiform mole included maternal age of 35 years and above (aOR 13.5;
CI: 1.46–125.31; p � 0.00), gestational age beyond the first trimester at the time of uterine evacuation (aOR 6.2; CI: 1.07–36.14;
p � 0.04), and history of previous abortion (aOR 4.3; CI: 1.00–18.57; p � 0.05). Conclusion. 'e prevalence of complete
hydatidiformmole was high at 6.1%. Associated risk factors included advancedmaternal age (35 years and above), history of previous
abortions, and gestational age beyond the first trimester at the time of evacuations. Recommendations. We recommend putting in
place capacity to do routine histopathological examination of all products of conception especially those at high risk for a molar
gestation either by clinical suspicion or by risk factors including advanced maternal age, advanced gestational age, and history of
previous abortion because of high prevalence of complete mole.
1. Introduction
Hydatidiform moles (HMs) are forms of gestational tropho-
blastic disease (GTD) that involve villous formation. 'ey are
characterized histologically by aberrant changes within the
placenta. Specifically, the chorionic villi in these placentas
show varying degrees of trophoblastic proliferation and oe-
dema of the villous stroma. Hydatidiform moles are catego-
rized as either complete hydatidiformmoles (CHMs) or partial
hydatidiformmoles (PHMs) based on biology and genetics [1].
Hydatidiformmole is the premalignant form of gestational
trophoblastic neoplasia. It is of clinical and epidemiological
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interest because of its potential for significant consequences
for women’s health [2].
Of the two forms of molar disease, complete hydatidi-
form moles are more clinically important as they have high
propensity for persistence (requiring clinical intervention)
or progression to choriocarcinoma. Of complete moles,
15–20%will continue on to develop gestational trophoblastic
neoplasia, whereas <5% of partial moles do. Complete
hydatidiform moles are androgenic gestations, typically
diploid but occasionally tetraploid. Partial hydatidiform
moles are triploid conceptuses with the extra haploid set of
chromosomes being paternally derived. Both types of moles
are typically followed clinically for persistence by serum
hCG levels and clinical symptoms (e.g., vaginal bleeding and
persistent pregnancy symptoms) [3].
'e incidence of molar pregnancy varies by geographical
region. It is generally believed that the incidence is high in
developing countries. 'e incidence is higher in women
younger than 20 years and older than 40 years of age. It is
also higher in nulliparous women, in patients of low eco-
nomic status, and in women whose diets are deficient in
protein, folic acid, and carotene [4].
Besides age, history of failed pregnancy increases the
incidence of GTD. For example, elective abortion and
miscarriage are connected with increasing risk of molar
pregnancy [1].
Molar pregnancies are one etiology for pregnancy fail-
ure. 'e gold standard for a molar diagnosis is by histo-
pathologic examination of the products of conception. 'e
practice of routine histopathologic evaluation of tissue
obtained at the time of abortion has been the subject of
debate because some authors think that it is not necessary as
the clinical significance of findings is low with low incidence
of HM [5].
'e usual management of abortions is not sufficient to
detect all molar pregnancies because tissue is not routinely
submitted for histological examination especially in
resource-limited regions [6].
By routine histopathologic assessment of products of
first-trimester spontaneous abortions, important patholo-
gies such as molar pregnancy and placental trophoblastic
neoplasia can be diagnosed [7].
'e histopathologic diagnosis of molar pregnancies can
be difficult and often requires expertise in perinatal pa-
thology [8].
Ancillary studies such as genotyping and ploidy analyses
are helpful but not universally available. Immunohisto-
chemistry (IHC) offered in many pathology laboratories can
be diagnostic for complete hydatidiform moles taking ad-
vantage of their androgenetic origin.
p57 is the gene product of the paternally imprinted,
maternally expressed gene CDKN1C, a cyclin-dependent
kinase inhibitor gene located on chromosome 11p15.5 [9].
It is expressed preferentially off the maternal allele and is
therefore not expressed in complete hydatidiform molar
villous stroma.
Our study sought to determine the incidence of HM in
our population of women requiring uterine evacuation for
failed pregnancies at a large referral hospital in Western
Uganda. We diagnosed HM by full gross and histopath-
ologic examination and confirmed the diagnosis with p57
IHC and review by an experienced perinatal pathologist
(DJR).
2. Materials and Methods
'is was a cross-sectional study carried out from November
2016 to February 2017 to determine the prevalence and
clinical factors associated with hydatidiform mole among
patients undergoing uterine evacuation at Mbarara Regional
Referral Teaching Hospital.
Using the Kish formula, the minimum sample size was
175 [10]. Patients admitted with abortions both spontaneous
and therapeutic including those suspicious for molar
pregnancies by ultrasound were included in the study. See
Figure 1 for recruitment strategy. All patients underwent
ultrasonography before evacuation. 'e products of con-
ception were kept in a container (500ml jar) [11] with 10%
buffered neutral formalin immediately after evacuation and
taken to the MUST pathology laboratory for pathologic
examination. Tissue processing was done using standard
procedures: following fixation, the entire specimen was
transferred to tissue cassettes and processed using an au-
tomatic Histokinette processor. Routine 5μ sections were
stained with haematoxylin and eosin, and slides were eval-
uated by theMUSTpathologists, and a subset were confirmed
by a perinatal pathologist (DJR).
Immunohistochemical (IHC) p57 analysis was per-
formed on all histopathologically diagnosed moles at the
pathology laboratory at Massachusetts General Hospital in
the USA. 'e IHC procedure employed a mouse mono-
clonal antibody (Leica Cat. # NCL-p57 Clone 25B2 diluted at
1:100), pretreated with EDTA pH 9.0 for 20 minutes and then
stained on a BOND III autostainer. Slides were reviewed for
immunoreactivity in the villous stroma using decidua as an
internal positive control.
Data on sociodemographics, medical conditions, obstet-
rics, and gynecological factors were obtained by consultation
with the referring clinicians. Patients were interviewed using
Patients who met the inclusion criteria
were consented, enrolled, and given
study identification numbers (N = 185)
Patients admitted with abortions and
suspicious molar pregnancy (N = 224)
Data analysis and final sample size
(N = 181)
Excluded complete
abortions and 
threatened abortions
(N = 39)
Excluded due to
2 blood clots,
2 missing data, and
laboratory mishaps
Non molar: n = 170 Molar: n = 11
Figure 1: Flow diagram on recruitment.
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a semistructured interviewer-administered questionnaire
by the principal investigator and the research assistants.
Questionnaire was filled in a private room in Gynaecological
Ward after uterine evacuation. For age, parity, last normal
menstrual period, history of previous abortion, type of
previous abortion, contraceptive use, cigarette smoking, and
tribe, we based on the participant’s self-report. Univariate
and multivariate analyses were computed using STATA 13.
3. Results
'emean age at presentation was 27.90± 7.1. Majority of the
participants were married, Banyankole from the Mbarara
district with a low socioeconomic status, and had attained
a primary level of education. Majority of the participants
were neither smokers nor alcohol consumers (Table 1).
By histopathology, the vast majority of the specimens
were nonmolar (93.9%) (Figure 2), some with greater than
usual inflammation (9.9%) and some without chorionic villi
present (26%) but with gestational endometrium and blood
clot only (presumed status after complete abortion).
'e prevalence of hydatidiform mole was 6.1% (11/181),
and all patients had complete mole confirmed by immuno-
histochemistry for p57 (Figure 3). Of the 13 patients with
ultrasound scan diagnosis of molar pregnancy who underwent
suction curettage, only 9 (69.2%) were confirmed to be
complete moles, while 2 patients with clinically unsuspected
molar pregnancy (by ultrasound scan) were identified after
surgical evacuation for abortions (2/168; 1.2%).
Some numerical discrepancies are observed for con-
traception use as 50 (27.62%) study participants did not use
any contraceptive method; for income, some women did
not willingly want to give any information about their
income; for the gestation age at evacuation, some women
included in the study could not recall their last normal
menstrual period.
As shown in Table 2, maternal age of 35 years and above,
history of previous abortion, and gestational age beyond the
first trimester at the time of uterine evacuation were found to
be significantly and independently associated with complete
mole. 'e odd of having complete mole is 13.5 times higher
than in patients with maternal age of less than 25 years, 6.2
times higher in patients with gestational age beyond the first
trimester, and 4.3 times higher in patients with history of
previous abortion.
4. Discussion
In our study, the prevalence of hydatidiformmole was found
at 6.1% among patients admitted for uterine evacuation. It is
difficult to compare our prevalence with that in published
reports due to the paucity of studies in sub-Saharan Africa
with histopathologic validation of the diagnosis.
Our prevalence is lower than the rates of 12.8% in
Tanzania reported in a cross-sectional study in a similar
setting [12]. But in this study in Tanzania, there was no
quality control by expert review or special studies. 'ey
reported 20/180 (11.1%) as partial mole and 3/180 (1.7%) as
complete mole. 'e diagnosis of partial hydatidiform mole
Table 1: Sociodemographic and behavioral characteristics of
patients.
Characteristic n n (%)
Age categories (years) 175<25 67 (38.3)
25–34 67 (38.3)≥35 41 (23.4)
District 181 120 (66.3)
Mbarara 30 (16.6)
Isingiro 16 (8.8)
Kiruhura 15 (8.3)
Others
Residence type 177
Rural 93 (52.5)
Urban 84 (47.5)
Tribe 178
Banyankole 157 (88.2)
Baganda 7 (3.9)
Bakiga 4 (2.2)
Others 10 (5.6)
Religion 177
Catholic 51 (28.8)
Protestant 92 (52.0)
Moslem 19 (10.7)
Others 15 (8.5)
Highest level of education 179
None 20 (11.2)
Primary 85 (47.5)
Secondary 55 (30.7)
Tertiary 19 (10.6)
Marital status 181
Single 29 (16.0)
Married 152 (84.0)
Occupation 181
Housewife 41 (22.6)
Business 45 (24.9)
Peasant 57 (31.5)
Student 9 (5.0)
Professional 29 (16.0)
Monthly income status 151<100k 89 (58.9)>100k 62 (41.1)
Alcohol consumption 174 13 (7.5)
Cigarette smoking 180 4 (2.2)
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Figure 2: 'e histopathological findings.
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based solely on histopathology is difficult even for experi-
enced pathologists [8]. 'eir report of 1.7% of complete
moles is lower than our findings of 6.1%. We suggest that, in
the study in Tanzania, many of the cases diagnosed as partial
hydatidiform moles were in fact complete moles and many
others likely nonmolar, but this would require reexamina-
tion of their histology to confirm. Our findings are in better
agreement with other reports. For example, in Germany,
Horn et al. found a similar prevalence, to ours, of 5.1% of
HM, specifically complete hydatidiform mole confirmed
with a molecular genotyping [13].
'e preevacuation molar diagnosis (by ultrasound scan)
in our study was observed in 13 patients, and 69.2% (9/13)
were confirmed to be complete mole by histopathology,
expert review, and immunohistochemistry diagnosis which
has a higher suspicion rate compared to the study in the UK
by Heath et al. where 2 (25%) were histologically confirmed
molar pregnancy in 8 women diagnosed preoperatively by
an ultrasound examination [14]. However, 2 patients with
unsuspected molar diagnosis (2/168, 1.2%) were found to be
complete mole in our study which follows between 1.16 and
12% as reported by Charry et al. [15].
Extremes of age have been a well-described risk factor for
molar pregnancies [1].We found that advancedmaternal age
was significantly associated with a diagnosis of hydatidiform
mole. It is likely that the oocytes of the older women are
more apt to unnatural fertilization [16]. Studies show
a significant increase in risk in women with pregnancy above
the age of 35 years and even further increase of 10-fold
beyond the age of 40 years [17].
Previous history of abortion was reported in 44
(24.3%) participants of our study, and 7 (15.9%) of them
were found to have complete mole. We found this history
to be strongly associated with a diagnosis of hydatidiform
mole, which is in accordance with others [1, 11, 18].
Hydatidiform mole was found to be more common in
women with history of two or more abortions as well in
the study in Ethiopia [18].'is could be due to the fact that
(a) (b)
(c) (d)
(e) (f)
Figure 3: Complete hydatidiform mole slides. Histology and immunohistochemistry of two of the cases of complete hydatidiform
mole. (a) Case MP115/17 H&E at 4x original showing enlarged villi with circumferential trophoblasts. Same case with p57 im-
munohistochemistry showing negative stromal and cytotrophoblast staining at 4x original (b) and 20x original (c). Note the
syncytiotrophoblast stains focally positive in the nucleus and faintly in the cytoplasm. (d) H&E at 4x original of case MP1211/16; note
the variety of villous sizes with cisternae and some with circumferential trophoblast hyperplasia. p57 immunohistochemistry at 4x
original (e) and 10x original (f); note the lack of villous stromal reactivity but the presence of extravillous and villous syncytio-
trophoblast staining.
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many women do not know the nature of the previous
abortion because histopathological examination is rarely
done, yet hydatidiform mole may be one of the previous
causes because history of hydatidiform mole has been
established as a strong risk factor for subsequent hyda-
tidiform mole [19].
Table 2: Univariate and multivariate logistic regression analyses for factors associated with hydatiform mole.
Variable No CM, n (%) CM, n (%) cOR (95% CI) p value aOR (95% CI) p value
Age categories (years) 0.0013 0.0053<25 66 (98.5) 1 (1.5) 1.0 1.0
25–34 65 (97.0) 2 (3.0) 2.0 (0.18–22.95) 1.5 (0.13–17.43)≥35 33 (80.5) 8 (19.5) 16 (1.92–133.36) 13.5 (1.46–125.31)
Previous abortion 0.051
Yes 37 (84.1) 7 (15.9) 6.3 (1.75–22.65) 0.0041 4.3 (1.00–18.57)
No 133 (97.1) 4 (2.9) 1.0 1.0
Gestational age 0.1718 0.042
1st trimester 75 (97.4) 2 (2.6) 1.0 1.0
2nd trimester 81 (91.0) 8 (8.9) 3.7 (0.76–18.00) 6.2 (1.07–36.14)
Monthly income status 0.0243<100k 80 (89.9) 9 (10.1) 6.9 (0.85–55.63)>100k 61 (98.4) 1 (1.6) 1.0
Parity 0.0916
Nulliparous 49 (98.0) 1 (2.0) 1.0
Primiparous 31 (96.9) 1 (3.1) 1.6 (0.09–26.20)
Multiparous 70 (93.3) 5 (6.7) 3.5 (0.40–30.89)
Grand multiparous 19 (82.6) 4 (17.4) 10.3 (1.08–98.31)
Maternal blood group/rhesus status
A+ NA
Yes 31 (88.6) 4 (11.4) 2.6 (0.71–9.30)
No 139 (95.2) 7 (4.8) 1.0
A− 0.1888
Yes 4 (100.0) 0 (0.0) NA
No 166 (93.8) 11 (6.2) 1.0
B+ NA
Yes 32 (88.9) 4 (11.1) 2.5 (0.68–8.93)
No 138 (95.2) 7 (4.8) 1.0
B− NA
Yes 2 (100.0) 0 (0.0) NA
No 168 (93.8) 11 (6.1) 1.0
AB+ 0.0867
Yes 4 (100.0) 0 (0.0) NA
No 166 (93.8) 11 (6.2) 1.0
O+ NA
Yes 91 (96.8) 3 (3.2) 0.32 (0.83–1.27)
No 79 (90.8) 8 (9.2) 1.0
O− 0.1590
Yes 3 (100.0) 0 (0.0) NA
No 167 (93.8) 11 (6.2) 1.0
History of contraceptive use of oral pills NA
Yes 19 (86.4) 3 (13.6) 2.98 (0.73–12.21)
No 151 (94.9) 8 (5.0) 1.0
Progesterone only pills 0.8406
Yes 6 (100.0) 0 (0.0) NA
No 164 (93.7) 11 (6.3) 1.0
Injectaplan 0.6218
Yes 72 (93.5) 5 (6.5) 1.1 (0.33–3.86)
No 98 (94.2) 6 (5.8) 1.0
Norplant NA
Yes 24 (96.0) 1 (4.0) 0.6 (0.74–4.97)
No 146 (93.6) 10 (6.4). 1.0
IUD NA
Yes 1 (100.0) 0 (0.0) NA
No 169 (93) 11 (6.1)
CM, complete mole; cOR, crude odds ratio; CI, confidence interval; aOR, adjusted odds.
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However, our study cannot advance knowledge on the
issue of the number of previous abortions and the ages at
abortion of these patients.
In our study, the parity, socioeconomic status, blood
group, and history of contraception use were not associated
with hydatidiform mole.
'ere were no partial hydatidiformmoles in our 181 cases.
'is may be because partial moles are more difficult to di-
agnose by morphology alone [20] but are likely due to our
sample size. 'e published incidence of histopathologically
and ploidy analysis verified partial hydatidiformmole is about
1 in 700 first- and second-trimester abortions [21], and rates
in East Africa are not known. Although our perinatal pa-
thologist did not review all 181 cases, she reviewed all the cases
the MUST pathologist diagnosed as mole and 10% of other
slides as part of quality control, and there was no discrepancy.
Our study is one of the largest studies in the literature of
an Eastern African population. Our results highlight the
utility/importance of histopathologic examination of prod-
ucts of conception.We suggest that all products of conception
from high-risk patients (women of advance maternal age,
those with histories of previous abortions, and those pre-
senting beyond the first trimester) be examined pathologically
to rule out a hydatidiform mole.
5. Conclusion
'e prevalence of complete hydatidiform mole confirmed
histopathologically by a perinatal pathologist and confirmed
by p57 testing was high at 6.1%. 'e following factors were
found to be independently associated with complete mole
among patients evacuated at Mbarara Regional Referral
Hospital: maternal age of 35 years and above, history of
previous abortion, and gestational age beyond the first
trimester at the time of evacuation. We recommend putting
in place capacity to do routine histopathological examina-
tion of all products of conception because of high prevalence
of complete mole. We recommend a cohort study aimed to
determine risk factors of hydatidiform mole and to de-
termine the outcome of patients with hydatidiform mole
undergoing uterine evacuation at MRRH.
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